NCT01728818View on ClinicalTrials.gov

Afatinib as Cancer Therapy for Exocrine Pancreatic Tumours

PHASE2UnknownINTERVENTIONAL

Enrollment

119

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2018

Conditions

Focus of Study Instead

Interventions

DRUG

Gemcitabine

1000 mg/m² d1,8,15 q4weeks

DRUG

Afatinib

40mg flat dose, po, once daily

DRUG

Gemcitabine

1000 mg/m², d1,8,15 q4weeks

Trial Locations (1)

81377

University of Munich, Munich

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

PD Dr. med. Volker Heinemann

OTHER